Genoa Ventures
VC Fund
San Francisco, United States
Genoa Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Genoa Ventures invests in early-stage life sciences technology companies. They fund entrepreneurs and companies looking to change the way science gets done with new tools and technologies. Sector focus areas include research tools, molecular diagnostics, synthetic biology, and industrial biology.Genoa Ventures was founded in 2014 by Jenny Rookeand is based in San Francisco, California, United States.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 38%
- Fund size:
- $84M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Genoa Ventures invests in
Stages Genoa Ventures invests in
Countries Genoa Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.5M–$6M
- Series A
- $9.5M–$33M
- Series B
- $7.1M–$34M
Investment Focus
Industry
- Biotechnology 24 (60%)
- Health Care 13 (33%)
- Life Science 5 (13%)
- Medical 4 (10%)
- Pharmaceutical 4 (10%)
Stage
- Series A 16 (40%)
- Series B 9 (23%)
- Seed 8 (20%)
- Series C 4 (10%)
- Funding Round 3 (8%)
Country
- United States 26 (65%)
- France 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jenny Rooke
Founder & Managing Director
|
Founder & Managing Director | Total investments: 27 | Find email | |
Jonathan Burbaum
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Landon Merrill
principal
|
principal | Total investments: 1 | Find email | |
Paul Conley
Partner
|
Partner | Total investments: 22 | Find email | |
William (Bill) Hyun
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epitel
|
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $26M / Series B / Jul 28, 2026 | |
Tropic Biosciences
|
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $105M / Series C / Mar 12, 2026 | |
Hermes Biosciences
|
Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently, and reproducibly from any bodily fluid or cell culture media. This technology aims to advance research into exosome function and support clinical applications in oncology, degenerative disease, and regenerativemedicine. | $6M / Seed / Nov 18, 2025 | |
Aqtual
|
Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology and biochemistry for chronic disease. | $31M / Series B / Jul 10, 2025 | |
Alida Biosciences
|
Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $7.5M / Series A / Jun 12, 2024 | |
|
Aqtual
|
Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology and biochemistry for chronic disease. | $16M / Series A / Oct 31, 2023 | |
BRAINBox Solutions
|
BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems. | $7.1M / Series B / Oct 30, 2023 | |
BrightSpec
|
LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | $18.4M / Series C / Dec 14, 2022 | |
ZwitterCo
|
ZwitterCo provides revolutionary membrane solutions for the treatment of highly-impaired wastewater. | $33M / Series A / Sep 15, 2022 | |
Fellow Health
|
Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M / Series A / Aug 01, 2022 | |
| See all 40 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Genoa Ventures invest in?
Genoa Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Genoa Ventures's check size?
Genoa Ventures typically joins rounds of $1.5M–$6M at Seed, $9.5M–$33M at Series A and $7.1M–$34M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genoa Ventures participates in.
How do I contact Genoa Ventures?
Public channels for Genoa Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Genoa Ventures?
The team at Genoa Ventures includes Jenny Rooke (Founder & Managing Director), Jonathan Burbaum (Venture Partner) and Landon Merrill (principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
